Opexa Therapeutics Inc  

(Public, NASDAQ:OPXA)   Watch this stock  
Find more results for OPXA
0.380
+0.002 (0.53%)
After Hours: 0.530 +0.150 (39.47%)
Aug 28, 7:27PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.34 - 0.41
52 week 0.30 - 1.47
Open 0.38
Vol / Avg. 436,490.00/371,613.00
Mkt cap 20.18M
P/E     -
Div/yield     -
EPS -0.45
Shares 53.39M
Beta 2.15
Inst. own 12%
Nov 4, 2015
Q3 2015 Opexa Therapeutics Inc Earnings Release (Estimated) Add to calendar
Sep 10, 2015
Opexa Therapeutics Inc at Rodman & Renshaw Global Investment Conference - 12:05PM EDT - Add to calendar
Aug 12, 2015
Q2 2015 Opexa Therapeutics Inc Earnings Call
Aug 12, 2015
Q2 2015 Opexa Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -481.47% -1183.45%
Operating margin -483.17% -1184.67%
EBITD margin - -1154.19%
Return on average assets -90.73% -79.13%
Return on average equity -164.99% -107.45%
Employees 39 -
CDP Score - -

Address

2635 Technology Forest Blvd
THE WOODLANDS, TX 77381-3905
United States - Map
+1-281-2729331 (Phone)
+1-281-8728585 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company engaged in developing a personalized immunotherapy with the potential to treat illnesses, including multiple sclerosis (MS). MS is an inflammatory autoimmune disease of the central nervous system (CNS), which is made up of the brain, spinal cord and optic nerves, with a clinically heterogeneous and unpredictable course that persists for decades. The Company is into development of a drug named Tcelna, which has the potential to fundamentally address the root cause of MS by stopping the demyelination process and supporting the generation of new myelin sheaths where demyelination has occurred (remyelination). Tcelna is an autologous T-cell immunotherapy that is being developed for the treatment of SPMS and is specifically tailored to each patient’s immune response profile to myelin.

Officers and directors

Neil K. Warma President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Karthik Radhakrishnan CFA Chief Financial Officer
Age: 44
Bio & Compensation  - Reuters
Donna R. Rill Chief Development Officer
Age: 61
Bio & Compensation  - Reuters
Timothy C. Barabe Director
Age: 62
Bio & Compensation  - Reuters
Hans-Peter Hartung M.D., Ph.D. Director
Age: 60
Bio & Compensation  - Reuters
Gail J. Maderis Independent Director
Age: 57
Bio & Compensation  - Reuters
Michael S. Richman Independent Director
Age: 54
Bio & Compensation  - Reuters
Scott B. Seaman CPA Independent Director
Age: 59
Bio & Compensation  - Reuters